{"id":"W4308026783","doi":"10.1136/jitc-2022-005780","title":"FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital; Université Laval; Juravinski Cancer Centre; Université du Québec à Montréal","funders":"National Center for Advancing Translational Sciences; Foundation Medicine; EMD Serono; Genentech; European Society for Medical Oncology; Shionogi; Natera; Seagen; Pfizer; Incyte; Jounce Therapeutics; Astellas Pharma; Eisai; Ono Pharmaceutical; Eli Lilly and Company; National Comprehensive Cancer Network; National Cancer Institute; Gilead Sciences; Calithera Biosciences; Celldex Therapeutics; Ipsen; Array BioPharma; Karyopharm Therapeutics; Exelixis; Sanofi; Memorial Sloan-Kettering Cancer Center; Dana-Farber/Harvard Cancer Center; Bristol-Myers Squibb; AstraZeneca; American Society of Clinical Oncology; GlaxoSmithKline; Amgen; Dana-Farber Cancer Institute","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Oncology; Tolerability; Renal cell carcinoma; Discontinuation; Combination therapy; Hazard ratio; Clinical endpoint; Progression-free survival; Adverse effect; Clinical trial; Cancer; Immunotherapy; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009989814,0.0004609224,0.0009504882,0.0003278461,0.0004210893,0.0006399875,0.0006767306,0.0004704821,0.003702543],"category_scores_gemma":[0.0003898292,0.0001369145,0.0007413349,0.000270409,0.0003027531,0.0005268639,0.0003609613,0.0008657022,0.0007996587],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001524498,"about_ca_system_score_gemma":0.001909184,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001398494,"about_ca_topic_score_gemma":0.005926952,"domain_scores_codex":[0.9996901,0.00005322976,0.0000195606,0.00009152208,0.00004597527,0.00009970211],"domain_scores_gemma":[0.9997045,0.00003456989,0.00005788952,0.00002788374,0.0000171149,0.0001579426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2349476,0.01795939,0.05702673,0.001907376,0.001825191,0.001538618,0.000326797,0.009104046,0.04746341,0.001394924,0.01185567,0.6146504],"study_design_scores_gemma":[0.1796085,0.5105132,0.1708195,0.0003960397,0.002224521,0.008273898,0.0001843972,0.01191635,0.03759107,0.001530412,0.07679044,0.0001517804],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9829915,0.006057871,0.001021768,0.0003542339,0.0001614838,0.00146231,0.001083458,0.0001984387,0.006668961],"genre_scores_gemma":[0.993552,0.0008876124,0.001618347,0.0003661058,0.00008246823,0.0003841962,0.001206189,0.00001881203,0.001884215],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003702543,"threshold_uncertainty_score":0.01238626,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02410113479203347,"score_gpt":0.3518191333851835,"score_spread":0.32771799859315,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}